ATE296106T1 - Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc - Google Patents

Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc

Info

Publication number
ATE296106T1
ATE296106T1 AT00912310T AT00912310T ATE296106T1 AT E296106 T1 ATE296106 T1 AT E296106T1 AT 00912310 T AT00912310 T AT 00912310T AT 00912310 T AT00912310 T AT 00912310T AT E296106 T1 ATE296106 T1 AT E296106T1
Authority
AT
Austria
Prior art keywords
dna
mcc
composition
cancer cells
prostate cancer
Prior art date
Application number
AT00912310T
Other languages
German (de)
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of ATE296106T1 publication Critical patent/ATE296106T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5063Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068Cell membranes or bacterial membranes enclosing drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00912310T 1999-04-01 2000-03-30 Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc ATE296106T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12745199P 1999-04-01 1999-04-01
PCT/CA2000/000342 WO2000059518A2 (en) 1999-04-01 2000-03-30 Composition and method for inducing apoptosis in prostate cancer cells

Publications (1)

Publication Number Publication Date
ATE296106T1 true ATE296106T1 (de) 2005-06-15

Family

ID=22430191

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00912310T ATE296106T1 (de) 1999-04-01 2000-03-30 Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc

Country Status (10)

Country Link
EP (1) EP1165106B8 (https=)
JP (1) JP2002541114A (https=)
AT (1) ATE296106T1 (https=)
AU (1) AU780909B2 (https=)
CA (1) CA2366090C (https=)
CY (1) CY1107455T1 (https=)
DE (1) DE60020352T2 (https=)
ES (1) ES2238996T3 (https=)
PT (1) PT1165106E (https=)
WO (1) WO2000059518A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033879A1 (en) * 1998-12-04 2000-06-15 Bioniche Life Sciences Inc. Method for the treatment of inflammation
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법

Also Published As

Publication number Publication date
AU3413500A (en) 2000-10-23
DE60020352D1 (de) 2005-06-30
EP1165106B8 (en) 2005-07-27
WO2000059518A2 (en) 2000-10-12
JP2002541114A (ja) 2002-12-03
DE60020352T2 (de) 2005-10-20
WO2000059518A3 (en) 2001-02-01
CA2366090C (en) 2011-05-24
PT1165106E (pt) 2005-10-31
EP1165106A2 (en) 2002-01-02
EP1165106B1 (en) 2005-05-25
CA2366090A1 (en) 2000-10-12
ES2238996T3 (es) 2005-09-16
AU780909B2 (en) 2005-04-21
CY1107455T1 (el) 2012-12-19

Similar Documents

Publication Publication Date Title
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
EP0781092A4 (en) METHOD FOR SENSITIZING TUMOR CELLS WITH ADENOVIRUSE1A
TR200400149T2 (tr) Tümörlerin teşhisi ve tedavisi için mikroorganizmalar ve hücreler
BR9709015A (pt) Quinolina carboxamidas como inbidores de tnf e como inbidores de pde-iv
ATE324888T1 (de) Krebstherapie
DE60027768D1 (de) Behandlung von metastatischer krankheit
ID26620A (id) Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi
EA200300934A1 (ru) Агенты и способы, предназначенные для лечения опухолевых заболеваний
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
PL374675A1 (en) Use of urease for inhibiting cancer cell growth
DE69533873D1 (de) Krebstherapie mit lymphotoxin
IS2254B (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
ATE296106T1 (de) Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
WO2004013313A3 (en) Antisense nucleic acids
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
EA200601630A1 (ru) Ниосома, имеющая внедрённый в неё маталлопорфириновый комплекс, способ её получения и лекарственное средство с её использованием
DK0579791T3 (da) Cellulær sammensætning til behandling af menneske- og dyreorganismer
ATE290390T1 (de) Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand
MXPA05009715A (es) Anticuerpo contra antigeno especifico de tumor como objetivo.
Joshi et al. Comparison of three mammalian cell-lines with respect to their sensitivities to hyperthermia, γ-rays and UV-radiation
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
WO2004001027A8 (en) Oligonucleotide inhibitors of mbd2/dna demethylase and uses thereof
DE69919386D1 (de) Zusammensetzung zur behandlung von entzündungen
CO5300456A1 (es) Compuestos y metodos para el tratamiento y diagnostico del cancer de prostata

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165106

Country of ref document: EP